HC Wainwright Issues Optimistic Estimate for XENE Earnings

Posted by Brian Himes on Aug 11th, 2026

Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) – Equities research analysts at HC Wainwright lifted their Q3 2026 earnings per share (EPS) estimates for Xenon Pharmaceuticals in a report released on Friday, August 7th. HC Wainwright analyst D. Tsao now forecasts that the biopharmaceutical company will earn ($1.07) per share for the quarter, up from their prior forecast of ($1.10). HC Wainwright has a “Buy” rating and a $74.00 price target on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($4.92) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals’ Q4 2026 earnings at ($1.13) EPS, FY2026 earnings at ($4.48) EPS, Q2 2027 earnings at ($1.21) EPS, Q3 2027 earnings at ($1.22) EPS, Q4 2027 earnings at ($1.24) EPS, FY2027 earnings at ($4.88) EPS, FY2028 earnings at ($3.89) EPS, FY2029 earnings at ($2.23) EPS and FY2030 earnings at ($0.18) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.05. During the same period in the previous year, the firm earned ($1.07) earnings per share.

A number of other brokerages have also recently issued reports on XENE. Royal Bank Of Canada cut their price objective on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating for the company in a research note on Friday. Wells Fargo & Company reiterated an “overweight” rating and issued a $69.00 price objective on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Wall Street Zen upgraded Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. Needham & Company LLC dropped their price objective on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $77.13.

Check Out Our Latest Stock Analysis on XENE

Xenon Pharmaceuticals Price Performance

NASDAQ:XENE opened at $64.23 on Tuesday. The company has a market capitalization of $6.21 billion, a price-to-earnings ratio of -13.55 and a beta of 0.62. The business has a 50 day moving average of $60.45 and a 200 day moving average of $54.46. Xenon Pharmaceuticals has a 1-year low of $32.78 and a 1-year high of $72.66.

Insider Buying and Selling

In related news, Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the sale, the director owned 1,455 shares of the company’s stock, valued at $77,318.70. This trade represents a 44.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gary Patou sold 1,322 shares of Xenon Pharmaceuticals stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the sale, the director owned 24,896 shares in the company, valued at approximately $1,322,973.44. This trade represents a 5.04% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.91% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Xenon Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in Xenon Pharmaceuticals in the second quarter worth about $454,057,000. Avoro Capital Advisors LLC lifted its stake in shares of Xenon Pharmaceuticals by 0.5% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,424,444 shares of the biopharmaceutical company’s stock valued at $243,124,000 after purchasing an additional 24,444 shares during the period. Janus Henderson Group PLC boosted its position in shares of Xenon Pharmaceuticals by 2.3% during the first quarter. Janus Henderson Group PLC now owns 4,175,982 shares of the biopharmaceutical company’s stock valued at $242,858,000 after purchasing an additional 91,948 shares in the last quarter. Wellington Management Group LLP grew its stake in Xenon Pharmaceuticals by 66.0% in the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock worth $144,936,000 after purchasing an additional 1,435,096 shares during the period. Finally, Capital International Investors grew its stake in Xenon Pharmaceuticals by 7.3% in the fourth quarter. Capital International Investors now owns 3,414,959 shares of the biopharmaceutical company’s stock worth $153,058,000 after purchasing an additional 233,466 shares during the period. 95.45% of the stock is owned by institutional investors.

Xenon Pharmaceuticals News Roundup

Here are the key news stories impacting Xenon Pharmaceuticals this week:

Positive Sentiment: HC Wainwright improved its EPS outlook for Q3 2026 to a loss of $1.07 from $1.10, Q4 2026 to a loss of $1.13 from $1.16, and full-year 2026 to a loss of $4.48 from $4.52. The firm also raised its FY2027, FY2028, FY2029 and FY2030 forecasts, indicating expectations for a faster reduction in losses and improving long-term financial performance.
Positive Sentiment: The FY2030 estimate was upgraded to a loss of $0.18 per share from $0.37, while FY2027 improved to a loss of $4.88 from $5.00. Although Xenon remains unprofitable, the revisions suggest it is moving closer to breakeven over time, which can support investor sentiment for a development-stage biopharmaceutical company.
Neutral Sentiment: HC Wainwright’s estimates imply continued substantial losses through 2029, including projected losses of $4.88 per share in FY2027 and $3.89 in FY2028. The stock’s valuation therefore remains dependent on clinical and commercial execution rather than current earnings.

Xenon Pharmaceuticals Company Profile

(Get Free Report)

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.